JERSEY CITY, N.J., Dec. 17, 2015 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced that the company recently conducted its Clinical Trial Transparency Leadership Forum, part of TrialScope's Transparency Leadership Series which is designed to bring leaders in life sciences companies together to discuss and debate current and emerging clinical trial transparency and compliance topics.
Each of the Forum programs are developed around specific topics or themes that are timely and important to compliance leaders. The December Forum included discussions of global disclosure performance and was highlighted by a presentation by Jennifer Miller, PhD. Assistant Professor, Division of Medical Ethics, NYU School of Medicine's Department of Population Health and President of Bioethics International entitled, "The Good Pharma Scorecard". Thomas Wicks, Chief Strategy Officer at TrialScope also presented findings from TrialScope's Clinical Trial Disclosure Maturity Model. The presentations and ensuing discussions highlighted the importance of measuring disclosure performance as well as the marketplace perception of such performance while also noting the challenges that most life sciences companies face when developing global disclosure policies.
Mike Forgash, CEO, TrialScope, commented, "TrialScope's Transparency Leadership Forum was an exceptional event that enabled industry leaders to step away from their desks and talk about important strategic and operational topics that impact clinical trial transparency programs with industry peers. The program is founded on the idea that these leaders can share their rationales, best practices, and challenges in an intimate setting with the goal of learning and improving existing disclosure performance."
Thomas Wicks, Chief Strategy Officer, noted, "The Transparency Leadership Series provides a unique opportunity for our industry peers to collaborate in a non-competitive environment. We purposely design plenty of discussion time into the program so participants get maximum value from their time together. In this Forum, we addressed disclosure performance as a collection of important metrics that tell a sponsor's compliance story. We also heard the concern about how that story is viewed by the market and the potential impact it has on brand integrity. We plan to offer similar programs in the New Year and will look to current participants to help us shape the agenda and prioritize discussion topics."
About TrialScope
TrialScope simplifies the complexities of clinical transparency management. TrialScope is a proven solution that has been implemented successfully and rigorously tested in the most complex environments with solutions that are currently implemented at 13 of the top 30 global clinical trial sponsors, including 6 of the top 10. The company's market-driven solutions and expertise enable sponsors to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater compliance. TrialScope technology is offered via a validation-ready SaaS platform hosted in a private cloud.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.